Skip Navigation
The Collection >
Nimodipine Capsules (marketed as Nimotop).
FDA Alert for Healthcare Professionals [US Food and Drug Administration Web site]. January 2006.

This U.S. Food and Drug Administration alert reminds health care professionals that nimodipine should only be administered orally, and that intravenous or parenteral administration can cause serious adverse events.
Free full text icon indicating hyperlink to external website
Information icon indicating hyperlink to external website
white box
Related Resources
COMMENTARY
Getting to the Root of the Matter
Flanders SA, Saint S. AHRQ WebM&M [serial online]. June 2005.
COMMENTARY
A Troubling Amine
Flynn EA. AHRQ WebM&M [serial online]. September 2006.
PRESS RELEASE/ANNOUNCEMENT
FDA public health notification: MRI-caused injuries in patients with implanted neurological stimulators.
Schultz DG. Rockville, MD: Center for Devices and Radiological Health, Food and Drug Administration; May 10, 2005.
View all related resources...
white box
Download: Adobe Reader   email icon Email
tan box
Find Related Resources by...
Resource Type   
style=
Target Audience  
style=
Clinical Area  
style=
Safety Target  
style=
Approach to Improving Safety  
style=
Origin/Sponsor  
white box